Replimune Group (NASDAQ:REPL) Trading Up 6% Following Analyst Upgrade

Replimune Group, Inc. (NASDAQ:REPL)’s share price was up 6% on Wednesday after HC Wainwright raised their price target on the stock from $17.00 to $21.00. HC Wainwright currently has a buy rating on the stock. Replimune Group traded as high as $12.41 and last traded at $12.57. Approximately 67,909 shares changed hands during trading, a decline of 91% from the average daily volume of 795,967 shares. The stock had previously closed at $11.85.

REPL has been the topic of several other research reports. Jefferies Financial Group raised their price target on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. BMO Capital Markets boosted their price objective on Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a research note on Friday, November 22nd. Finally, JPMorgan Chase & Co. raised their target price on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $17.86.

Insider Transactions at Replimune Group

In related news, CEO Sushil Patel sold 10,000 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the sale, the chief executive officer now owns 202,014 shares of the company’s stock, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Several institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC lifted its stake in shares of Replimune Group by 14.7% in the fourth quarter. SG Americas Securities LLC now owns 26,291 shares of the company’s stock valued at $318,000 after buying an additional 3,374 shares during the period. Algert Global LLC raised its position in Replimune Group by 5.4% in the second quarter. Algert Global LLC now owns 84,033 shares of the company’s stock worth $756,000 after purchasing an additional 4,340 shares in the last quarter. Creative Planning grew its stake in shares of Replimune Group by 28.7% in the 3rd quarter. Creative Planning now owns 21,047 shares of the company’s stock valued at $231,000 after purchasing an additional 4,699 shares during the period. Rhumbline Advisers boosted its position in Replimune Group by 7.2% in the second quarter. Rhumbline Advisers now owns 84,923 shares of the company’s stock valued at $764,000 after buying an additional 5,732 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Replimune Group by 82.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock valued at $144,000 after acquiring an additional 5,926 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Trading Up 4.9 %

The business has a 50 day simple moving average of $12.16 and a 200 day simple moving average of $11.24. The company has a market cap of $850.80 million, a price-to-earnings ratio of -4.08 and a beta of 1.28. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. As a group, equities analysts forecast that Replimune Group, Inc. will post -2.91 EPS for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.